Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uveal Melanoma 3 Melanoma 2 Leukemia, Myeloid, Acute 2 Carcinoma, Hepatocellular 2 Sarcoma 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Ichthyosis, X-Linked 1 HER2 Negative Metastatic Breast Cancer 1 Glioma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Advanced Solid Cancers 1 Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 126 Carboplatin 108 Pemetrexed 76 Paclitaxel 76 Cisplatin 73 Nivolumab 56 Docetaxel 53 Erlotinib Hydrochloride 50 Gemcitabine 49 Radiotherapy 48 Bevacizumab 32 osimertinib 31 Cetuximab 29 atezolizumab 25 Cyclophosphamide 25 durvalumab 24 130-nm albumin-bound paclitaxel 22 Oxaliplatin 19 Fluorouracil 18 Taxes 17 Radiosurgery 17 fludarabine 16 Magnetic Resonance Spectroscopy 16 Gefitinib 16 Ipilimumab 15 Vinorelbine 14 Leucovorin 14 Albumin-Bound Paclitaxel 14 Vorinostat 13 Radiation 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Carcinoma, Non-Small-Cell Lung × ADI PEG20 × Clear all

NCT03498222 2020-02-25

iTRAP

Queen Mary University of London

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡